Skin Activating Treatment Lotion

Product Overview

The Bioyona Skin Activating Treatment Lotion is the foundational hydration and bioactive delivery step in the Bioyona Skin Activating Treatment system, which also includes a companion serum, mist, cream, and UV protector. The lotion is formulated to deliver Totipotent Prostembryona Factor® (TPF) into the stratum corneum and upper viable epidermis, where growth factor and cytokine signalling can promote keratinocyte renewal, support the extracellular matrix, and modulate melanogenesis. The cold-water extraction process used to isolate TPF preserves the biological activity of thermolabile peptides, growth factors such as EGF (epidermal growth factor) analogues, and cytokines that would be denatured by conventional heat-based extraction methods.

In clinical and in vitro assessments, TPF has been shown to inhibit tyrosinase activity (the key enzyme in the melanin biosynthesis pathway), stimulate collagen synthesis by dermal fibroblasts, and accelerate the skin wound healing cascade through promotion of cell proliferation and differentiation. These properties make the Bioyona Skin Activating Treatment Lotion clinically relevant for patients presenting with hyperpigmentation, post-inflammatory melanosis, photodamage, fine lines, and loss of skin elasticity. EMIS Asia supplies the Bioyona Skin Activating Treatment range to aesthetic clinics, dermatology practices, and professional skincare providers across Singapore.

Specifications

Clinical Applications

• Melanin management and brightening: Tyrosinase inhibition by TPF reduces melanin overproduction in patients with post-inflammatory hyperpigmentation, solar lentigines, and UV-induced uneven skin tone — applicable in aesthetic and dermatology settings across Singapore's high-UV environment.
• Anti-ageing and collagen support: Promotion of dermal fibroblast collagen synthesis targets the progressive loss of type I and III collagen that underlies fine lines, skin laxity, and the reduction of dermal thickness observed with intrinsic and photoageing.
• Post-procedure skin recovery: The growth factor and cytokine content of TPF supports the cellular repair cascade following aesthetic procedures including chemical peels, laser resurfacing, and microneedling, reducing downtime and supporting orderly re-epithelialisation.
• Sensitive and reactive skin maintenance: The solvent-free, non-irritating formulation is appropriate for patients whose skin is sensitised by rosacea, seborrhoeic dermatitis, or contact allergy, where conventional active-heavy formulations may trigger flares.
• Combination anti-ageing protocol: Used as the lotion base in the full Bioyona Skin Activating Treatment system, layered with the TPF serum and cream, to deliver a comprehensive multi-depth bioactive programme targeting epidermis, dermo-epidermal junction, and dermal structural integrity.

Frequently Asked Questions

Q: What is Totipotent Prostembryona Factor® (TPF) and how does it differ from conventional growth factor skincare?
A: TPF is Bioyona's proprietary cold-water extract from deep-sea fish embryonic stem cells, yielding a complex of multiple peptides, growth factors (including EGF analogues), and cytokines in their native, bioactive conformation. Unlike synthetic single-peptide formulations or heat-processed growth factor extracts, the cold-water extraction process preserves the full spectrum of thermolabile bioactives and their natural intermolecular interactions. This multi-component profile allows TPF to act across several skin biology pathways simultaneously — tyrosinase inhibition, collagen synthesis, oxidative stress reduction, and cellular repair — rather than targeting a single mechanism.

Q: Is this product suitable for use alongside prescription skincare such as retinoids or hydroquinone?
A: The Bioyona Skin Activating Treatment Lotion is a bioactive-rich cosmeceutical that is generally compatible with prescription skincare when used as directed. In patients on retinoid therapy, the lotion's growth factor and peptide content may complement retinoid-driven collagen remodelling. Patients using prescribed hydroquinone for hyperpigmentation can layer the TPF lotion's tyrosinase-inhibitory effect for a dual-pathway brightening approach. Sequencing should be confirmed with the prescribing dermatologist for individual protocols.

Q: How soon can visible results be expected with the Skin Activating Treatment Lotion?
A: Initial improvements in skin hydration and surface texture are typically perceptible within 2–4 weeks of consistent twice-daily use. Measurable changes in pigmentation and fine lines, which reflect underlying collagen synthesis and melanogenesis modulation, generally require 6–12 weeks of regular application. Post-procedure recovery benefits, where growth factor signalling is most active, are observed more rapidly — often within 5–10 days following aesthetic treatment.

Q: Can aesthetic clinics in Singapore purchase the Bioyona range through EMIS Asia for professional use?
A: Yes. EMIS Asia supplies the full Bioyona Skin Activating Treatment range — lotion, serum, mist, cream, and UV protector — to aesthetic clinics, dermatology practices, and professional skincare providers in Singapore. Clinic pricing, tester units, and multi-unit procurement are available through the EMIS Asia B2B channel. The Bioyona system is positioned as a professional-grade treatment protocol suitable for use as clinic homecare and post-procedure maintenance.

Q: Is the Bioyona Skin Activating Treatment Lotion registered with the Health Sciences Authority (HSA) Singapore?
A: Cosmeceutical lotions and serums containing topical bioactive ingredients such as peptides and growth factor extracts are classified as cosmetic products in Singapore and do not require HSA product registration under the Cosmetic Products Safety Regulation (CPSR). However, cosmetic products sold in Singapore must comply with the ASEAN Cosmetics Directive (ACD), and EMIS Asia ensures that all Bioyona products supplied meet applicable ingredient safety and labelling standards for the Singapore market.